Publications by authors named "S Schraen"
Background: The use of cerebrospinal (CSF) biomarkers in the diagnosis of Alzheimer's disease (AD) has been gaining interest in clinical practice. Although their usefulness has been demonstrated, their potential value in older patients remains debated.
Objectives: To assess whether knowledge of the results of CSF AD biomarkers was associated with the same gain in diagnostic confidence in older adults > 80 than in younger patients.
Background And Objectives: To elaborate a new algorithm to establish a standardized method to define cutoffs for CSF biomarkers of Alzheimer disease (AD) by validating the algorithm against CSF classification derived from PET imaging.
Methods: Low and high levels of CSF phosphorylated tau were first identified to establish optimal cutoffs for CSF β-amyloid (Aβ) peptide biomarkers. These Aβ cutoffs were then used to determine cutoffs for CSF tau and phosphorylated tau markers.
Article Synopsis
- - The practice of measuring cerebrospinal fluid (CSF) biomarkers for diagnosing Alzheimer's disease (AD) is inconsistent across different medical centers, leading to varied interpretations of the same results.
- - A study involving 40 centers worldwide analyzed their analytical protocols and reports to create a consensus on how to interpret CSF biomarker profiles effectively.
- - The findings highlighted that while the analytical methods were largely similar, there was significant variability in how results were reported; as a result, harmonized reporting formats were established for clearer communication among laboratories.
Introduction: There is increasing interest in plasma amyloid beta (Aβ) as an endophenotype of Alzheimer's disease (AD). Identifying the genetic determinants of plasma Aβ levels may elucidate important biological processes that determine plasma Aβ measures.
Methods: We included 12,369 non-demented participants from eight population-based studies.